IM Cannabis introduces WAGNERS brand in Germany – New cannabis companies


IM Cannabis expects to export premium indoor-grown Canadian cannabis to the rapidly developing German medical cannabis market in 2022

TORONTO, ON, GLIL YAM, ISRAEL and BAD OLDESLOE, DEUTSCHLAND / ACCESSWIRE / December 7, 2021 / IM Cannabis Corp. (the “Company” or “IM Cannabis”) (CSE: IMCC, NASDAQ: IMCC), a global cannabis company with offices in Israel, Canada and Germany, is pleased to announce plans to launch its popular Canadian brand WAGNERS in 2022 at the Introduce the German medical cannabis market and begin exporting high quality indoor-grown dried flowers from IMC Canada’s grow facility in 2022, subject to regulatory approval. These plans are in line with the company’s vertically integrated multi-country strategy and follow the recently announced launch of WAGNERS in Israel and the receipt of an import permit for Canadian cannabis products from the Israeli Ministry of Health.

To learn more about WAGNERS, please visit WAGNERS – Well Made Weed ( ¹

Given the rapidly growing indoor demand for premium Canadian hemp hemp and an increasing number of German medical patients who do not rely on government reimbursements, we are excited to introduce our popular WAGNERS brand to medical patients in Germany.

Oren Shuster, CEO of IM Cannabis

We continue to lay our foundations in Germany, currently one of the largest medical cannabis markets in the world, which is expected to grow rapidly as Germany’s newly elected government adopts comprehensive regulatory reform of cannabis use. By using our global supply chain, IM Cannabis will continue to focus on significantly expanding our business in Germany in the short term and being well positioned for a possible regulatory reform through brand awareness.

IM Cannabis’s global infrastructure for international deliveries

IM Cannabis operates in Germany through Adjupharm GmbH, the company’s fully licensed EU GMP subsidiary (“Adjupharm” or “IMC Germany”), which recently completed construction of a new, state-of-the-art logistics center that enables the company to carry out all aspects of its supply chain, including repackaging cannabis in bulk. The company expects the logistics center to expand the company’s sales capabilities. In addition, the company’s operations in Germany are intended to serve as the center of a broader long-term European strategy. Since being acquired by IM Cannabis, Adjupharm has upgraded its manufacturing and storage capabilities to accommodate the surge in medical cannabis volumes from new supply contracts. With the completion of the logistics center, IM Cannabis has now doubled its presence in Germany to around 8,000 square feet, upgraded its production facilities with the latest technology and increased its storage capacity to seven tons of cannabis. With the operation of the logistics center, new sources of supply that expand the portfolio to include premium products, some of which are exclusive, and a broad network of sales partners, the company aims to strengthen and expand its presence on the German market.

IM Cannabis is available in Canada through Trichome Financial Corp. (“Trichome”) and its subsidiaries Trichome JWC Acquisition Corp. (“TJAC”) and MYM Nutraceuticals Inc. (“MYM” and together with Trichome and TJAC “IMC Canada”). . IMC Canada’s Manitou facility in Kitchener, Ontario is a 115,000 square foot indoor grow facility located just one hour from Toronto that is ICann GAP accredited as Good Agricultural and Collection Practices (“GACP”) was established as the company’s global cultivation center for export and processing in Germany and Israel.

About IM Cannabis Corp.

IM Cannabis (NASDAQ: IMCC, CSE: IMCC) is a leading international cannabis company providing premium products to medical patients and adult recreational users. IM Cannabis is one of the very few companies with offices in Israel, Germany, and Canada, the three largest federally legal markets. The ecosystem created by its international activities leverages the company’s unique data-driven perspective and product supply chain worldwide. With a commitment to responsible growth and financial prudence, and the ability to operate within the most stringent regulatory environments, the company has quickly grown to become one of the leading growers and distributors of high quality cannabis worldwide.

The IM Cannabis Ecosystem operates in Israel through its relationship with Focus Medical Herbs, which grows, imports, and distributes cannabis to medical patients using years of proprietary data and patient insights. The company also operates retail medical cannabis pharmacies, online platforms, distribution centers and logistics centers in Israel that enable the safe delivery and quality control of IM cannabis products along the entire value chain. In Germany, the IM cannabis ecosystem is operated by Adjupharm GmbH (“Adjupharm” or “IMC Germany”), where it also sells cannabis to pharmacies for medical patients. In Canada, IM Cannabis is available through Trichome Financial Corp. (“Trichome”) and its subsidiaries Trichome JWC Acquisition Corp (“TJAC”) and MYM Nutraceuticals Inc. (“MYM” and together with Trichome and TJAC “IMC Canada”). where it grows and processes cannabis for the adult market at its facilities in Ontario, Nova Scotia and Quebec under the WAGNERS and Highland Grow brands.


1 Canadian regulations only allow the export of cannabis for medical or scientific purposes. Exports to Germany are subject to the Canadian Cannabis Act.

Original press release

Published by NCV Newswire

NCV Newswire

New Cannabis Ventures’ NCV Newswire aims to curate high quality content and information on leading cannabis companies to help our readers filter out the noise and stay up to date on the major cannabis business news. The NCV Newswire is hand-curated by an editor and not automated anyway. Do you have a confidential news tip? Get in touch.

Get our Sunday newsletter